Equillium, Inc. (EQ) vs ImmuCell Corporation (ICCC)

Equillium, Inc. and ImmuCell Corporation are both Biotechnology companies. Equillium, Inc. and ImmuCell Corporation are of similar size ($91.3M and $88.6M). Equillium, Inc. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 114×. Equillium, Inc. grew revenue faster over the last twelve months: 13.9% against 8.49%. ImmuCell Corporation has the higher net margin (2.57% vs 0.00%) and the higher return on invested capital (7.84% vs 0.00%). Across the 17 metrics below, ImmuCell Corporation leads on 12 and Equillium, Inc. on 5.

Valuation

Metric EQ ICCC Biotechnology median
P/E n/m 114.07 8.68
P/S 3.89 2.85 10.29
P/B 2.85 2.79 2.40
Price to free cash flow n/m 20.67 20.52
EV/EBITDA n/m 13.82 0.68
EV/Sales 2.68 2.83 10.15
Earnings yield (13.99%) 0.88% (28.86%)
Free cash flow yield (12.56%) 4.84% (22.44%)

Profitability

Metric EQ ICCC Biotechnology median
Gross margin 100.00% 40.32% 65.16%
Operating margin 0.00% 12.60% 0.00%
Net margin 0.00% 2.57% 0.00%
Free cash flow margin 0.00% 13.79% 0.00%
Return on equity (58.98%) 2.57% (56.66%)
Return on assets (50.68%) 1.69% (49.22%)
Return on invested capital 0.00% 7.84% 0.00%

Growth

Metric EQ ICCC Biotechnology median
Revenue growth (TTM) 13.89% 8.49% 5.64%
EPS growth (last fiscal year) (69.57%) 53.85% 30.08%
Revenue growth, 5-year CAGR — 12.50% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EQ ICCC Biotechnology median
Debt to equity 0.00 0.26 0.00
Current ratio 23.40 4.75 4.72
Net debt to EBITDA 1.29 1.19 0.96

Dividend

Metric EQ ICCC Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric EQ ICCC Biotechnology median
Market cap 91.31m 88.55m 150.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack